Literature DB >> 9099311

Fractures and phenylketonuria.

L G Greeves1, D J Carson, A Magee, C C Patterson.   

Abstract

Parent or self-reported history of fractures in a group of patients aged from 0.3 to 33.6 years on dietary treatment for phenylketonuria was studied by means of a questionnaire. Twenty-one of 85 patients had a history of fracture compared with 18/98 sibling controls. There was no significant difference in the lifetime risk of fracture between patients and controls (chi 2 = 1.43, df = 1, p = 0.23), but a significantly higher risk of fracture was reported over the age of 8 y (chi 2 = 5.11, df = 1, p = 0.024), with a relative risk of 2.6 (95% confidence interval 1.1.6.1). We suggest this may be related either to deterioration in dietary control in this age group or to a cumulative disease-related or diet-related reduction in bone mass.

Entities:  

Mesh:

Year:  1997        PMID: 9099311     DOI: 10.1111/j.1651-2227.1997.tb08882.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  16 in total

1.  Elevated plasma phenylalanine concentrations may adversely affect bone status of phenylketonuric mice.

Authors:  S Yannicelli; D M Medeiros
Journal:  J Inherit Metab Dis       Date:  2002-09       Impact factor: 4.982

2.  Analysis of the functional muscle-bone unit of the forearm in patients with phenylketonuria by peripheral quantitative computed tomography.

Authors:  Daniela Choukair; Carolin Kneppo; Reinhard Feneberg; Eckhard Schönau; Martin Lindner; Stefan Kölker; Georg F Hoffmann; Burkhard Tönshoff
Journal:  J Inherit Metab Dis       Date:  2016-11-22       Impact factor: 4.982

3.  Bone metabolism and the muscle-bone relationship in children, adolescents and young adults with phenylketonuria.

Authors:  Piotr Adamczyk; Aurelia Morawiec-Knysak; Paweł Płudowski; Beata Banaszak; Jacek Karpe; Wojciech Pluskiewicz
Journal:  J Bone Miner Metab       Date:  2010-08-13       Impact factor: 2.626

Review 4.  A systematic review of bone mineral density and fractures in phenylketonuria.

Authors:  Karen E Hansen; Denise Ney
Journal:  J Inherit Metab Dis       Date:  2014-07-09       Impact factor: 4.982

Review 5.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

Review 6.  Advances in the nutritional and pharmacological management of phenylketonuria.

Authors:  Denise M Ney; Robert D Blank; Karen E Hansen
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2014-01       Impact factor: 4.294

7.  Low bone strength is a manifestation of phenylketonuria in mice and is attenuated by a glycomacropeptide diet.

Authors:  Patrick Solverson; Sangita G Murali; Suzanne J Litscher; Robert D Blank; Denise M Ney
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

8.  A long-term study of bone mineral density in patients with phenylketonuria under diet therapy.

Authors:  Hala M Koura; Nagwa Abdallah Ismail; Ashraf F Kamel; Azza M Ahmed; Amal Saad-Hussein; Laila K Effat
Journal:  Arch Med Sci       Date:  2011-07-11       Impact factor: 3.318

9.  Body composition profile of young patients with phenylketonuria and mild hyperphenylalaninemia.

Authors:  Artemis Doulgeraki; Astrinia Skarpalezou; Areti Theodosiadou; Ioannis Monopolis; Kleopatra Schulpis
Journal:  Int J Endocrinol Metab       Date:  2014-07-01

10.  Peak bone mass in patients with phenylketonuria.

Authors:  D Modan-Moses; I Vered; G Schwartz; Y Anikster; S Abraham; R Segev; Ori Efrati
Journal:  J Inherit Metab Dis       Date:  2007-03-08       Impact factor: 4.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.